Join The Lazy Contractor's Blueprint live on Nov 28 — show up and get 1,000 free Mindy creditsJoin The Lazy Contractor's Blueprint, free and live on Nov 28
Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination
DEPT OF DEFENSE
Notice type
Solicitation
Solicitation #
HT9427-26-R-E020
NAICS
541715
PSC
AN13
Posted
November 10, 2026
Response due
November 20, 2026
Place of performance
28360, MD
What this opportunity is
The Department of Defense is seeking a contractor to develop a prototype for a Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination product, which must include both a physical barrier and antimicrobial properties. This opportunity is suited for small businesses under NAICS 541715, particularly those with capabilities in medical product development and FDA approval processes. Interested firms should note that this is a solicitation notice, indicating they should track the opportunity closely for updates and amendments, including a revised proposal due date of November 20, 2026.
Analysis by Mindy, grounded in the SAM.gov notice.
Description
This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections.
This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product.
The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance).
The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022.
NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0003 only extends the proposal due date).
Amendment 0001 – removed alternate point of contact information under “Contract Information” on SAM.gov
Amendment 0002 – revised proposal due date from: 12:00pm eastern, Friday, 23 Oct 2026 to: 12:00pm eastern Friday, 06 Nov 2026
Amendment 0003 – revised proposal due date from: 12:00pm eastern Friday, 06 Nov 2026 to: 12:00pm eastern Friday, 20 Nov 2026
Source: SAM.gov, as posted. Verify the current solicitation before responding.
Pursue this opportunity with Mindy
See who holds it now, who else is bidding, and draft your response — grounded in real government data, not generic AI.